Literature DB >> 30539313

Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study.

Ana Nanette Tibubos1, Mareike Ernst2, Elmar Brähler2, Sabine Fischbeck3, Andreas Hinz4, Maria Blettner5,6, Sylke R Zeissig5,6, Veronika Weyer5, Barbara H Imruck2, Harald Binder7, Manfred E Beutel2.   

Abstract

PURPOSE: Fatigue has found increasing attention as a debilitating and lasting condition of cancer patients. However, it has remained unclear to what degree long-term survivors of malignant melanoma suffer from fatigue. Therefore, this study aimed to determine fatigue and its link with quality of life, aftercare behavior, and mental and physical symptoms among melanoma survivors.
METHODS: A register-based sample of 684 long-term survivors an average of 8.4 (SD = 1.72; range 5.67-12.17) years after diagnosis was compared to 2049 participants from a representative survey by the Multidimensional Fatigue Inventory. In a hierarchical linear regression, statistical predictors for fatigue were ascertained.
RESULTS: Overall fatigue was not increased in melanoma survivors except for younger melanoma survivors under 40 years. As in the general population, fatigue increased with age, and it was higher in women compared to men. Fatigue was associated with decreased quality of life, reduced functioning, and increased physical and mental symptoms. Substantial predictors (30% explained variance) were higher age, additional chronic illness, self-blame, detrimental interactions and lack of social support, and also fear of recurrence. There was neither an effect of medical parameters (clinical stage, time since diagnosis) nor of participation in follow-up care.
CONCLUSIONS: Fatigue needs to be taken seriously in the aftercare of melanoma survivors as it is associated with multiple functional and quality of life impairments and heightened distress. Reduction of fatigue in melanoma patients should address younger survivors (under 40 years) and older survivors (over 60 years) with additional chronic illness and focus on illness coping and social support.

Entities:  

Keywords:  Cancer; Fatigue; Malignant melanoma; Mental health

Mesh:

Year:  2018        PMID: 30539313     DOI: 10.1007/s00520-018-4587-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  6 in total

1.  Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.

Authors:  Lando Janssen; Nicole M A Blijlevens; Meggie M C M Drissen; Esmée A Bakker; Malou A H Nuijten; Jeroen J W M Janssen; Silvie Timmers; Maria T E Hopman
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

2.  Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study.

Authors:  Lisa Wiens; Norbert Schäffeler; Thomas Eigentler; Claus Garbe; Andrea Forschner
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

3.  Higher levels of stress and different coping strategies are associated with greater morning and evening fatigue severity in oncology patients receiving chemotherapy.

Authors:  Fay Wright; Kord M Kober; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski
Journal:  Support Care Cancer       Date:  2020-01-20       Impact factor: 3.603

4.  Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.

Authors:  Maha Mamoor; Michael A Postow; Jessica A Lavery; Shrujal S Baxi; Niloufer Khan; Jun J Mao; Lauren J Rogak; Robert Sidlow; Bridgette Thom; Jedd A Wolchok; Deborah Korenstein
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

Review 5.  Cancer-Related Fatigue: Causes and Current Treatment Options.

Authors:  Melissa S Y Thong; Cornelis J F van Noorden; Karen Steindorf; Volker Arndt
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

6.  Measuring physical, cognitive, and emotional aspects of exhaustion with the BOSS II-short version - results from a representative population-based study in Germany.

Authors:  Antonia M Werner; Bjarne Schmalbach; Markus Zenger; Elmar Brähler; Andreas Hinz; Johannes Kruse; Hanna Kampling
Journal:  BMC Public Health       Date:  2022-03-24       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.